| | |
| Clinical data | |
|---|---|
| Other names | L-arginyl-L-lysyl-L-α-aspartyl-L-valyl-L-tyrosine |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| NIAID ChemDB | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.242.320 |
| Chemical and physical data | |
| Formula | C30H49N9O9 |
| Molar mass | 679.776 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Thymopentin is a thymic polypeptide derivative which interacts with T cells and acts as an immunostimulant. [1] [2] [3] [4] As such, it was used in several clinical studies in the early years of the AIDS pandemic (from 1983 to 1985). Thymopentin helped to improve immunological condition in some patients for a brief time under specific treatments. [5] [6] [7] It has also been investigated more recently for applications in the treatment of rheumatoid arthritis, [8] and lung cancer. [9]